What is glofitamab?

Medically reviewed by Carmen Pope, BPharm. Last updated on June 6, 2025.

Official Answer by Drugs.com

Glofitamab-gxbm is an immunotherapy treatment that may be used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy. Glofitamab-gxbm is approved under the name Columvi.

Large B-cell lymphoma is an aggressive type of non-Hodgkin’s lymphoma (NHL) resulting from the malignant proliferation of B cells during their various stages of development. LBCL is one of the most prevalent types of blood cancer among adults.

Glofitamab-gxbm represents a much needed further treatment option for B-cell lymphoma patients and its approval was based on impressive results including a 56% overall response rate and a complete response rate of 43%. 68.5% of patients experienced a long-lasting response of 9 months or longer (median duration of response, 18.4 months).

Columvi belongs to a new class of medicines known as CD20×CD3 T-cell engaging bispecific monoclonal antibodies. It was granted accelerated approval by the FDA on June 15, 2023.

References

Shirley M. (2023). Glofitamab: First Approval. Drugs, 1–7. Advance online publication. https://doi.org/10.1007/s40265-023-01894-5
Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser; Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study. Blood 2022; 140 (Supplement 1): 1775–1777. doi: https://doi.org/10.1182/blood-2022-157732
Wang, C., Liu, Y. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. J Hematol Oncol 16, 20 (2023). https://doi.org/10.1186/s13045-023-01420-w
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., Wu, S. J., Cartron, G., Hertzberg, M., Sureda, A., Perez-Callejo, D., Lundberg, L., Relf, J., Dixon, M., Clark, E., Humphrey, K., … Hutchings, M. (2022). Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England journal of medicine, 387(24), 2220–2231. https://doi.org/10.1056/NEJMoa2206913

What is the cost of Kymriah?

Kymriah (tisagenlecleucel) is an expensive CAR-T cell cancer therapy costs over $612,000 for one treatment infusion, but most people do not pay this amount. In addition, the Centers for Medicare & Medicaid Services (CMS) states that CAR-T cell therapy would be covered for eligible people with Medicare. Continue reading

What is the cost of Yescarta?

The cost of Yescarta is about $424,000 per treatment regimen, but most people do not pay this amount. Your insurance or the manufacturer may cover many of the costs for this treatment. Each dose of Yescarta is a customized treatment created using a patient’s own immune system to help fight lymphoma (a type of blood cancer).

Is Adcetris a chemotherapy drug?

Adcetris is used to treat cancer but is not a traditional chemotherapy. Adcetris combines an antibody and a cancer drug, allowing the antibody to direct the drug to a target on lymphoma cancer cells known as CD30. It is used for certain types of blood cancers in adults and children. Continue reading

What is glofitamab?

Read next

What is the cost of Kymriah?

What is the cost of Yescarta?

Is Adcetris a chemotherapy drug?

See also:

Qulipta

Aimovig

Dupixent

Ubrelvy

Nurtec ODT

Xeomin

Dysport

Botox Cosmetic

Arazlo

Tazorac

Related medical questions

Related support groups